19 April 2022: Clinical Research
Factors Associated with Non-Adherence for Prescribed Treatment in 201 Patients with Multidrug-Resistant and Rifampicin-Resistant Tuberculosis in Anhui Province, China
Qing-Qing Zhu 1BCDE* , Jie Wang 23BCDE* , Napoleon Bellua Sam 4F , Jie Luo 5F , Jie Liu 1A* , Hai-Feng Pan 23A*DOI: 10.12659/MSM.935334
Med Sci Monit 2022; 28:e935334
Table 1 Patient awareness of multidrug-resistant tuberculosis and rifampicin-resistant tuberculosis.
| Awareness rate (%) | |
|---|---|
| Could MDR/RR-TB be cured? | 76.0 |
| Is MDR/RR-TB more severe and difficult to cure than ordinary tuberculosis? | 92.5 |
| If MDR/RR-TB infects others, will they also become MDR/RR-TB once they fall ill? | 64.8 |
| Do the drugs to treat MDR/RR-TB have any adverse effects on humans? | 79.4 |
| Can I reduce the dose or type of medication at will? | 89.0 |
| Can I stop treatment when I feel that my symptoms have subsided? | 82.2 |
| Should I stop smoking and drinking if have MDR/RR-TB? | 94.5 |
| Is MDR/RR-TB hereditary? | 92.0 |
| Which institution should I go to for medical service of MDR/RR-TB? | 59.0 |